Chimeric and humanized antibodies to alpha5beta1 integrin that modulate angiogenesis
Details for Australian Patent Application No. 2003298783 (hide)
International Classifications
Event Publications
6 May 2004 Complete Application Filed
Priority application(s): 60/429,743 26.11.02 US
19 August 2004 Application Open to Public Inspection
Published as AU-B-2003298783
23 April 2009 Assignment before Grant
PDL BioPharma, Inc. The application has been assigned to Facet Biotech Corporation 2004
4 November 2010 Application Accepted
Published as AU-B-2003298783
20 January 2011 Alteration of Name
The name of the applicant has been altered to Abbott Biotherapeutics Corp. 2004
3 March 2011 Standard Patent Sealed
Legal
The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.
Next and Previous Patents/Applications
2003298784-LABELING APPARATUS AND METHOD OF MAKING SAME
2003298782-ADHESIVE ARTICLES, METHOD FOR MAKING AND USES FOR SAME
IP Reporting Samples
Customised IP Reporting
IP Insider for IP Professionals
IP Monitor Professional
- Editable Word format reports
- For IP Professionals
- Multiuser